AdAlta Ltd (ASX:1AD) managing director Dr Tim Oldham tells Proactive the company is seeking an early return to clinical trials of its lead asset, AD-214, with a $3.5 million non-renounceable rights offer. AdAlta has already received commitments from investors for $2.49 million of the target amount.
AdAlta to support early return to clinical trials of AD-214 with rights offer
